Becton, Dickinson and Company (NYSE:BDX) Shares Purchased by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. boosted its holdings in Becton, Dickinson and Company (NYSE:BDXFree Report) by 47.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 358,847 shares of the medical instruments supplier’s stock after purchasing an additional 114,808 shares during the quarter. Balyasny Asset Management L.P. owned approximately 0.12% of Becton, Dickinson and Company worth $87,498,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in BDX. Norges Bank acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at $761,798,000. Ontario Teachers Pension Plan Board grew its position in Becton, Dickinson and Company by 242.8% during the third quarter. Ontario Teachers Pension Plan Board now owns 1,783,769 shares of the medical instruments supplier’s stock valued at $461,158,000 after acquiring an additional 1,263,391 shares during the period. Vanguard Group Inc. grew its position in Becton, Dickinson and Company by 2.0% during the third quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock valued at $6,703,041,000 after acquiring an additional 516,427 shares during the period. Royal Bank of Canada grew its position in Becton, Dickinson and Company by 28.5% during the third quarter. Royal Bank of Canada now owns 2,139,493 shares of the medical instruments supplier’s stock valued at $553,121,000 after acquiring an additional 473,914 shares during the period. Finally, Morgan Stanley grew its position in Becton, Dickinson and Company by 4.5% during the third quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock valued at $2,637,062,000 after acquiring an additional 435,168 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Becton, Dickinson and Company

In related news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at $542,348.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Roland Goette sold 3,300 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $236.73, for a total value of $781,209.00. Following the sale, the executive vice president now owns 11,308 shares in the company, valued at approximately $2,676,942.84. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,597 shares of company stock valued at $2,028,786. Insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on BDX. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, June 6th. The Goldman Sachs Group began coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 price target for the company. Finally, Barclays boosted their price target on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research report on Monday, May 6th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $280.17.

View Our Latest Report on BDX

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $239.68 on Tuesday. Becton, Dickinson and Company has a 1-year low of $224.00 and a 1-year high of $287.32. The business has a 50-day moving average of $235.68 and a 200-day moving average of $238.03. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97. The company has a market capitalization of $69.27 billion, a price-to-earnings ratio of 52.79, a PEG ratio of 2.11 and a beta of 0.44.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, topping the consensus estimate of $2.97 by $0.20. The company had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The company’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.86 earnings per share. On average, equities analysts anticipate that Becton, Dickinson and Company will post 13.03 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be issued a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 1.59%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Recommended Stories

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.